on CureVac (NASDAQ:CVAC)
CureVac Appoints Axel Sven Malkomes as CFO
CureVac N.V., a biopharmaceutical company focusing on mRNA technology, has announced Axel Sven Malkomes as its new Chief Financial Officer, effective November 11, 2024. Malkomes brings over 30 years of experience in finance and investment banking.
The appointment aligns with CureVac's growth phase. Dr. Alexander Zehnder, CEO of CureVac, expressed confidence that Malkomes' expertise will strengthen the company’s financial strategies and shareholder value.
Previously, Malkomes was CFO at Cardior Pharmaceuticals, playing a key role in its acquisition by Novo Nordisk. He also held CFO roles at Medigene AG and senior positions in healthcare investment banking.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CureVac news